Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension

dc.contributor.author	BLANCO GARCIA, FRANCISCO JAVIER
dc.date.accessioned	2017-06-07T06:57:48Z
dc.date.available	2017-06-07T06:57:48Z
dc.date.issued	2015
dc.identifier.issn	2326-5191
dc.identifier.uri	http://hdl.handle.net/20.500.11940/1077
dc.language.iso	eng
dc.title	Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
dc.type	Publicación de congreso
dc.authorsophos	Edwards, Christopher J.
dc.authorsophos	Blanco, Francisco J.
dc.authorsophos	Crowley, Jeffrey
dc.authorsophos	Hu, ChiaChi
dc.authorsophos	Shah, Kamal
dc.authorsophos	Birbara, Charles A.
dc.identifier.isi	370860204390
dc.identifier.sophos	17902
dc.issue.number	s10
dc.journal.title	Arthritis and Rheumatology
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña::INIBIC.- Instituto de Investigación Biomédica
dc.organization	Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario A Coruña::Reumatoloxía
dc.rights.accessRights	openAccess
dc.typesophos	Comunicaciones a congresos
dc.volume.number	67

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.